Page 1

Interim report for Q3 2020/21 Ambu's revenue increased organically by 7 % in Q3 and 16 % for the year to date mainly driven by new product launches in Visualization and uptake in elective procedures in Europe and North America . Full - year outlook as of 1 July 2021 is maintained . " We continue our strong growth trajectory on the back of our innovation and commercial execution . I'm proud of how the organization is responding effectively to the continued COVID - 19 market volatility and supply chain disruption . As we continue to roll out our pipeline , we will emerge as the leading single - use endoscopy player , " says Juan Jose Gonzalez , CEO of Ambu . Highlights for the quarter Comparative figures for Q3 2019/20 are stated in brackets . ● Q3 RESULTS ● ● ● Ambu Revenue for Q3 was DKK 973m ( DKK 947m ) based on organic growth of 7 % ( 21 % ) . Reported growth for the quarter was 3 % ( 23 % ) . Year to date , organic growth was 16 % ( 20 % ) , with reported growth of 11 % ( 22 % ) . Growth rates are significantly influenced by the high comparables for Q3 2019/20 . Compared to Q3 2018/19 , before the pandemic , the annual average organic growth rate was 14 % . Sales in North America grew organically by 32 % ( -10 % ) , while we saw a decline in Europe of -10 % ( 59 % ) . Rest of World posted organic growth of 7 % ( 31 % ) . Year to date , organic growth rates were : North America 16 % ( 7 % ) , Europe 16 % ( 38 % ) and Rest of World 11 % ( 15 % ) . Visualization sales were on par with the sales in Q3 last year , which means 0 % growth ( 81 % ) as Q3 last year was a quarter with extraordinarily high Visualization sales . The annual average organic growth rate for Visualization compared to Q3 2018/19 is 36 % . Year to date , organic Visualization growth was 29 % ( 60 % ) . Sales of single - use endoscopes reached 386,000 units in the quarter and 1,135,000 units year to date . Sales volumes were thus up 15 % and 37 % , respectively , relative to last year . Anaesthesia sales declined by -1 % ( -1 % ) , while Patient Monitoring & Diagnostics ( PMD ) posted organic growth of 44 % ( -32 % ) . Year to date , Anaesthesia was flat at 0 % ( 3 % ) and PMD grew by 7 % ( -10 % ) . TM In early Q4 , we submitted aScopeTM Gastro and aBoxTM 2 for FDA clearance , and the 1.5 version of the aScope T Duodeno is progressing as planned with commercialization expected to commence in September 2021. Launch of aScope ™ 5 Broncho is postponed to 2021/22 . Gross margin for the quarter was 62.5 % ( 64.7 % ) . The gross margin year to date was 63.4 % ( 62.2 % ) . The declining gross margin is mainly driven by product mix . Ambu Company announcement no . 16 2020/21 17 August 2021 Page 1